drugset
drugset / Trial / NCT04341207

Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients

NCT04341207 ↗

Phase 2 Unknown 1000 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A). To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).

Timeline

Start
2020-04-03
Primary completion
2022-04
Completion
2022-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 250 mg —
Subject Hydroxychloroquine Small molecule 200 mg —

Indications

No indication recorded.